

To: Annual General Meeting of Hofseth BioCare ASA on 10 May 2024

From: The Nomination Committee of Hofseth BioCare ASA

Date: 2 May 2024

Issue no. 7 to the AGM agenda: Election of Board Members

Existing Board of Directors:

| Function | Name | Period |
|----------|-------------------------|-------------|
| Chair | Roger Hofseth | 2022 – 2024 |
| Director | Crawford Currie | 2022 – 2024 |
| Director | Torill Standal Eliassen | 2021 – 2023 |
| Director | Christoph Baldegger | 2021 – 2023 |
| Director | Amy Novogratz | 2021 – 2023 |

The election terms of the board members Roger Hofseth and Crawford Currie expire upon the annual general meeting in 2024. The Company's nomination committee recommends that both are re-elected as board members for a new election term of two years.

The election committee has evaluated the Board composition based on the current and coming growth phase in HBC and suggests re-election of directors Amy Novogratz and Christoph Baldegger, and suggest Linda Christin Hoff as new Chair, and Maria Öhlander Bech to replace Torill Standal Eliassen as director. Hence, the recommendation for the Board of Directors in HBC to be:

| Function | Name | Period |
|----------|---------------------|-------------|
| Chair | Linda Christin Hoff | 2024 – 2026 |
| Director | Crawford Currie | 2024 – 2026 |
| Director | Maria Öhlander Bech | 2024 – 2026 |
| Director | Christoph Baldegger | 2023 – 2025 |
| Director | Amy Novogratz | 2023 – 2025 |
| Director | Roger Hofseth | 2024 – 2026 |

Linda Christin Hoff:


Linda Christin Hoff has a MSc in Economics from BI Norwegian Business School and has attended the Executive Board Programme at INSEAD in Paris. She is an experienced finance professional with international expertise, and currently holds the position as Chief Credit Officer at Maritime&Merchant Bank ASA. She is also responsible for ESG within the bank. Previous experience includes being a CFO for start-ups and a SaaS company, heading up the finance team of Norske Skogindustrier ASA and 13 years in the Shipping, Offshore and Energy department of Nordea in New York, London and Oslo. She has held several board positions, and currently sits on the board of BillKill AS and the advisory board of House of Math AS.

Maria Öhlander Bech:

Maria Bech has 30 years' experience working across the pharmaceutical industry. With valuable expertise in drug development strategies, clinical programs, and study design, she has held key leadership positions in both clinical development and R&D, such as VP Clinical Development and Regulatory Affairs at Karo Bio AB and as Chief Scientific Officer in the nutrition company Smartfish

AS. Prior to her executive roles, Maria worked at AstraZeneca, where she coordinated various clinical programs and projects. Her experience spans across therapeutic areas including endocrinology, CNS, cardiovascular, respiratory, nutrition, and cancer. Maria holds an MSc in Molecular Biology from the University of Lund. In addition to her role as CEO at EpiEndo Pharmaceuticals Ehf, Maria is also a non-executive director at Paxman AB and Neuronano AB.

On behalf of the Nomination committee in Hofseth BioCare ASA,



Geir Even Håberg
Chair